NCT01028755View on ClinicalTrials.gov

To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions

Neoplasms

Interventions

DRUG

BAY79-4620

BAY79-4620 will be administered as 1 hour IV infusion. Dose escalation will be dependent on any dose limiting toxicities

Trial Locations (2)

37203

Nashville

78229-3307

San Antonio

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY